Blanket Purchase Agreement 36C24222A0007

The Department of Veterans Affairs Veterans Health Administration (VA-VHA) awarded a $2.5 million Blanket Purchase Agreement (BPA) to Optum Pharmacy 801, Inc., doing business as Avella Specialty Pharmacy, a subsidiary of UnitedHealth Group Incorporated. Under this single-award IDV, Avella will provide nationwide chemotherapy compounding services to support VA oncology and infusion treatment programs across the VHA's network of medical centers and clinics through November 2026. Avella has received numerous prior awards from the VA-VHA for specialized pharmacy services involving hazardous drug compounding, including individual delivery orders, multi-year Indefinite Delivery Contracts, and additional BPAs. The company performs the compounding work at its own facilities, frequently in Phoenix, Arizona, to fulfill the VA's requirements for customized chemotherapy agents, hazardous sterile preparations, intravenous solutions, and other medications based on patient-specific orders. No set-aside designations have been applied to Avella's prime contracts with VA-VHA thus far.

The VA-VHA has also issued several BPA call orders under this $2.5 million IDV, including a $100,000 firm fixed price contract for a one-year period of performance beginning November 2023, and a $500,000 renewal for another one-year period ending November 2023. Additionally, the agency awarded a $900,000 firm fixed price BPA call in November 2021 for chemotherapy compounding services to be performed in Phoenix, Arizona through November 2022. These task orders demonstrate Avella's role as a key supplier of compounded medications tailored to veterans' individual healthcare needs across the VHA's integrated service networks and treatment programs.